Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
about
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary diseaseIL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in miceFalls in patients with chronic obstructive pulmonary disease: a call for further research.Estrogen receptor-alpha as a drug target candidate for preventing lung inflammation.Effects and mechanism of bufei yishen formula in a rat chronic obstructive pulmonary disease model.Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines.Role of AMP-Activated Protein Kinase (AMPK) in Smoking-Induced Lung Inflammation and Emphysema.Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.RNAi Therapeutic Platforms for Lung Diseases.Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage.Optimising treatment for COPD--new strategies for combination therapyEmerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.Defining phenotypes in COPD: an aid to personalized healthcare.COPD-associated pulmonary hypertension: clinical implications and current methods for treatment.Budesonide mitigates pathological changes in animal model Of COPD through reducing neutrophil elastase expressionBudesonide ameliorates lung function of the cigarette smoke-exposed rats through reducing matrix metalloproteinase-1 content.The Challenges of Precision Medicine in COPD.Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study.
P2860
Q24187361-8FDCE5FE-1364-441B-A6F9-0A30CAF50073Q27311393-931A1A07-7B7A-4576-BDC8-8587E78A7CCCQ33157378-B1742821-3327-4EC6-A614-D7A7A1D57ABCQ33577529-534FF32D-1912-43F5-B57E-417076B061C0Q33735832-0062645C-7D12-402B-A699-EC216C8BCF7FQ34542774-33B406A8-911D-47F1-B220-B425A3E26EDFQ35028796-B460398C-F302-4936-9A92-3C104856CB04Q37120940-89ECA731-AD8F-4DC8-B0C9-B4B270AB37D7Q37277373-3E820902-C4FC-4BC4-A320-1AF123F78000Q37287627-4D62A9DE-4670-4788-BD9A-2B097B3411A4Q37336771-E25D299C-3968-47D3-9EF6-AE75432368F6Q37588723-52723E3E-C4C0-4362-8238-A4156CB70543Q38208244-E82C0C32-FA65-44A7-9DFB-93B1026C1C06Q38841456-CC4FD780-2615-42E9-90AD-5572D49F75A5Q41640230-E3D12B64-F497-4194-ADD7-10116DB4025DQ41645807-D62D66F7-2508-4F75-AB49-B5BE1C4C0608Q47962475-7A28E688-6C37-4D15-93F8-76C38C8EB2EAQ52564986-21C8CB33-9AE0-497C-A02D-70610F6D43E1
P2860
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
@en
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
@nl
type
label
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
@en
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
@nl
prefLabel
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
@en
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
@nl
P2093
P2860
P1476
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.
@en
P2093
Jeremy A Falk
Omar A Minai
Zab Mosenifar
P2860
P304
P356
10.1513/PATS.200707-096ET
P577
2008-05-01T00:00:00Z